Bicara Therapeutics (BCAX): Officer filed to sell ~$449K

~$449K

planned to sell · 25K shares, around Oct 21, 2026

Planned for

Oct 21, 2026

Notice filed

Oct 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 21, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
2. Oct 7, 20265% stakeT. Rowe Price Investment Management, Inc. reported a passive stake (13G) of 4.2%

What came next

1. Nov 9, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Bicara Therapeutics

For Bicara Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BCAX page.

How this filing works

• SEC Form 144
• Rule 10b5-1 trading plans

Other disclosures at Bicara Therapeutics

• SEC Schedule 13GOct 7, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 13, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its BCAX page.